A better Ozempic? Eli Lilly’s new obesity drug cut weight by 23%, study finds

In an added benefit, more than one in eight people taking the highest dose of Retratrutide were completely free of arthritic ...

Eli Lilly's Obesity Drug Dominance Still Underpriced By Market, Bank of America Says

Bank of America sees Eli Lilly's obesity drug growth underestimated, forecasting $3 billion Orfoglipron revenue by 2026 as new therapies expand global market leadership.

Eli Lilly Further Cements Itself As The King Of Weight Loss

Eli Lilly leads incretins via Zepbound/Mounjaro, retatrutide at 28.7% loss, $50B R&D and US buildout, 2025 guidance, ...

Exclusive: US FDA brass pushed internally for speedier Lilly weight-loss pill verdict

Leaders at the U.S. Food and Drug Administration have pressed internally for reviewers to speed up their evaluation of Eli ...

Lilly’s experimental shot cuts body weight by 23% in study

A next-generation obesity shot from Eli Lilly and Co. helped patients lose almost a quarter of their body weight, potentially ...
Stocktwits on MSN

The 2025 weight-loss drug gold rush: How Eli Lilly pulled ahead, Novo hit a snag — and a swarm of biotech underdogs are closing in

Global obesity-drug sales could exceed $130–150B by the mid-2030s, driven by GLP-1/GIP drugs and expanding access beyond the ...

Weight-loss drugs fill a treatment gap for women with hormone disorder PCOS, doctors say

Women with polycystic ovary syndrome are increasingly turning to blockbuster weight-loss drugs from Eli Lilly and Novo ...
BioSpace

Structure Stock Soars as Oral GLP-1 Generates ‘Highly Competitive’ Weight Loss

Structure's aleniglipron elicited over 11% weight loss in a Phase II trial, sending the biotech's stock up nearly 103% as ...